What is the Chemours securities class action lawsuit about?

The lawsuit alleges that The Chemours Company made false and/or misleading statements to investors during the class period from February 20, 2026 to August 4, 2026. Specifically, it alleges that Chemours materially overstated aftermarket demand for its Opteon products and issued unreliable financial guidance for fiscal year 2026 as a result of these undisclosed issues.

What did Chemours allegedly misrepresent about its Opteon products?

The lawsuit alleges that Chemours overstated aftermarket demand for its Opteon refrigerant products and failed to disclose that demand was decreasing. This decline allegedly resulted from Defendants' overselling of Opteon products in the preceding fiscal year, which artificially inflated near-term demand figures.

Who is eligible to join the Chemours securities class action?

Investors who purchased or acquired Chemours (NASDAQ: CC) securities between February 20, 2026 and August 4, 2026 may be eligible to participate in the class action. Affected investors should review their options before the lead plaintiff deadline of December 7, 2026.

What is the deadline to file a lead plaintiff motion in the Chemours lawsuit?

The deadline to seek appointment as lead plaintiff in the Chemours securities class action is December 7, 2026. Investors who wish to take an active role in the litigation must file their motion with the U.S. District Court for the District of Delaware by that date.

Where was the Chemours securities lawsuit filed?

The Chemours securities class action was filed in the U.S. District Court for the District of Delaware. The case concerns alleged misstatements made during the class period spanning February 20, 2026 through August 4, 2026.

Did Chemours allegedly mislead investors about its 2026 financial guidance?

The lawsuit alleges that Chemours's financial guidance for fiscal year 2026 was unreliable because it was based on overstated demand figures for its Opteon product line. As a result of these allegedly undisclosed issues, Defendants' public statements are alleged to have been materially false and misleading at all relevant times during the class period.

How does the Chemours class action relate to Opteon refrigerant sales?

The complaint alleges that Chemours oversold its Opteon refrigerant products in a prior fiscal year, which artificially pulled forward demand and caused aftermarket demand to subsequently decline. Defendants allegedly failed to disclose this dynamic to investors while continuing to make positive public statements about Opteon's demand outlook.

What should Chemours investors do if they lost money during the class period?

Investors who suffered losses on Chemours (NASDAQ: CC) securities purchased between February 20, 2026 and August 4, 2026 may have legal options, including joining the class action or seeking appointment as lead plaintiff. Consulting with a securities attorney before the December 7, 2026 lead plaintiff deadline can help investors understand their rights and potential remedies.

The Chemours Company - Faruqi & Faruqi LLP

The Chemours Company

Join Action

Case Details

Ticker CC

Class Period 02/20/2026 - 08/04/2026

Lead Plaintiff Deadline 12/07/2026

Days Left to Seek Lead Plaintiff

If you are a The Chemours Company investor who suffered a loss and would like to learn more, you can provide your information below:

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In The Chemours To Contact Him Directly To Discuss Their Options

If you purchased or acquired securities in The Chemours between February 20, 2026 and August 4, 2026 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310).

Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against The Chemours Company (“The Chemours” or the “Company”) (NYSE: CC) and reminds investors of the December 7, 2026 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company.

As detailed below, the complaint alleges that the Company and its executives violated federal securities laws by making false and/or misleading statements and/or failing to disclose that: Specifically, Defendants made false and/or misleading statements and/or failed to disclose that: (i) Defendants had materially overstated aftermarket demand for their Opteon products; (ii) demand for such products was decreasing as a result of Defendants’ overselling Opteon products in the preceding fiscal year; (iii) as a result of these undisclosed issues, Defendants’ financial guidance for the 2026 fiscal year was unreliable; and (iv) as a result, Defendants’ public statements were materially false and misleading at all relevant times.

Lead Plaintiff Deadline: December 7, 2026

Call Partner Josh Wilson at 877-247-4292 or 212-983-9330 (Ext. 1310). Or submit your information below to learn about your rights.

Join Action

The Chemours Company

Monetary Losses ($) *

Website URL

First Name *

Last Name *

Telephone *

Email *

Street Address

City

State

Zip Code

Purchases

1	Purchases Options Price per Share Date # of Shares Principal Amount Amount Paid Series or Cusip # of Contracts Price per Contract Exercise Price Expiration Date
1	Purchases Options Price per Share Date # of Shares Principal Amount Amount Paid Series or Cusip # of Contracts Price per Contract Exercise Price Expiration Date

Add Row

Sales

1	Sales Options Price per Share Date # of Shares Principal Amount Amount Paid Series or Cusip # of Contracts Price per Contract Exercise Price Expiration Date
1	Sales Options Price per Share Date # of Shares Principal Amount Amount Paid Series or Cusip # of Contracts Price per Contract Exercise Price Expiration Date

Add Row

Upload your trades here:

Accepted file types: xls, xlsx, doc, docx, pdf, jpg, jpeg, png, Max. file size: 50 MB, Max. files: 5.
You may redact account numbers from your uploaded documents.

File name:

File size:

Select File

Does not establish an attorney-client relationship *

By clicking this box, I acknowledge that this form is not intended to and does not establish an attorney-client relationship between myself and Faruqi & Faruqi LLP, and that the submission or receipt of information via this form, e-mail or telephone does not create an attorney-client relationship.

Case

Users to notify